Apyx Medical (APYX) Net Income towards Common Stockholders (2011 - 2026)

Apyx Medical's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$2.1 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 49.2% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (up 54.24% YoY) and the FY2025 annual result came in at -$11.2 million, up 52.22% from the prior year.
• Net Income towards Common Stockholders was -$2.1 million for Q1 2026 at Apyx Medical, down from -$1.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$1.0 million in Q2 2023 and bottomed at -$9.6 million in Q4 2023.
• A 5-year average of -$4.6 million and a median of -$4.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 81.3% — and 2024, when it tumbled 543.38%.
• Apyx Medical's Net Income towards Common Stockholders stood at -$6.1 million in 2022, then slumped by 58.4% to -$9.6 million in 2023, then jumped by 51.83% to -$4.6 million in 2024, then soared by 71.93% to -$1.3 million in 2025, then tumbled by 62.28% to -$2.1 million in 2026.
• Business Quant data shows APYX's Net Income towards Common Stockholders at -$2.1 million in Q1 2026, -$1.3 million in Q4 2025, and -$2.0 million in Q3 2025.